{"database": "lobbying", "table": "lobbying_activities", "rows": [[1884824, "f94a2f30-034b-442a-b17d-c8ba94dce0e1", "Q3", "RAMPY NORTHRUP LLC", 401103289, "AMERICAN CLINICAL LABORATORY ASSOCIATION (ACLA)", 2016, "third_quarter", "MED", "Implementation of P.L.113-93, Protecting Access to Medicare Act of 2014 (changes to reimbursement for clinical laboratory services). \nProposals concerning the Stark Law's in-office ancillary services exception. \nPolicies impacting Medicare reimbursement for clinical laboratory services. \nFDA regulation of clinical laboratory services. \nH.R.6, 21st Century Cures Act.", "Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE", 60000, null, 0, 0, "2016-10-19T08:57:37.317000-04:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["1884824"], "units": {}, "query_ms": 0.29951194301247597, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}